41 results about "Monomethylfumarate" patented technology

The present invention provides pharmaceutical compositions comprising compounds of Formula (I), and methods of treating neurological disorders comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound of Formula (I).

Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w / w to about 95% w / w.

The invention discloses a method for preparing contact lenses with a two-dimension code. The method comprises the following steps: 1) preparing raw materials, namely, A, mixing hydrogel, an emulsion stabilizer and a monomethyl fumarate sodium salt in parts by weight, heating, and treating with infrared rays and microwaves alternatively twice, thereby obtaining a first mixture; B, mixing silicone hydrogel with glycerinum in parts by weight, thereby obtaining a second mixture; C, mixing the first mixture and the second mixture, thereby obtaining a third mixture; D, mixing the third mixture, nano-silver granules and nano ferric hydroxide granules, feeding into water, and treating in ultrasonic waves, thereby obtaining a fourth mixture; 2) molding. By adopting the contact lenses prepared by using the method disclosed by the invention, eyes can be prevented from abrasion caused by a two-dimension code graph when people wear the contact lenses with the two-dimension code, and wearing comfort can be further improved; moreover, due to the two-dimension code added on the contact lenses, the contact lenses can be widely used in fields such as a recognition system, a security protection system or an anti-theft system, and the like.

Disclosed are conjugates of monomethyl fumarate and a carrier group or aminocarrier group, or a pharmaceutically acceptable salt thereof. In the conjugates, monomethyl fumarate acyl is covalently bonded to the carrier group or aminocarrier group through a carbon-oxygen bond that is cleavable in vivo. The carrier group may include a core, e.g., a monosaccharide, a sugar acid (e.g., acid monosaccharide), a sugar alcohol, or a catechin polyphenol. The aminocarrier group may include a core, e.g., an aminomonosaccharide. The carrier group or aminocarrier group may include, e.g., at least one short chain fatty acid acyl, at least one tryptophan analogue, at least one ketone body, or at least one preketone body. Also disclosed are pharmaceutical compositions containing the conjugates and methods of their use.

The present invention relates to novel compounds, e.g. for use as a medicament. In particular, the present invention relates to novel prodrugs of monomethyl fumarate (MMF) suitable as a medicament, preferably in the treatment and / or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis, rheumatoid arthritis and psoriasis.